CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Open Access
- 15 December 2009
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (2) , 268-275
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 49 references indexed in Scilit:
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progressionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II StudyJournal of Clinical Oncology, 2009
- Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinibAngiogenesis, 2009
- Cancer clinical trial outcomes: Any progress in tumour-size assessment?European Journal of Cancer, 2009
- Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial HypertensionThe American Journal of Pathology, 2008
- Plasticity of CD133+ cells: Role in pulmonary vascular remodelingCardiovascular Research, 2007
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000